PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes

Diabetes and Vascular Disease Research

Volumn 5, Issue 4, 2008, Pages 345-346

  Marx, Nikolaus ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE COURSE; FRACTURE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INTRAVASCULAR ULTRASOUND; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PERIPHERAL EDEMA;

CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 56249109450     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2008.048     Document Type: Note

References (7)

1. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 2005; 366:1279-89.
2. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
3. Marx N, Froehlich J, Siam L et al. The antidiabetic PPARg-activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease. Arterioscl Thromb Vasc Biol 2003;23: 283-8.
4. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81.
5. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003;42:1757-63.
6. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004;24:930-4.
7. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73.